Skip to main content
. 2023 May 9;10(5):203. doi: 10.3390/jcdd10050203

Table 2.

Summary of the studies’ characteristics included in the review.

Reference Methodological Evaluation (%) n Age (Years) Sex
(F/M)
MS Definition Analyzed Variables
Time Frequency Non-Linear
Aso et al., 2006 [31] 94% 104 43–70 Both
(48/52)
NCEP ATP III No HF, LF, LF/HF No
Stein et al., 2007 [21] 75% 899 67–76 Both
(56/44)
NCEP ATP III SDNN, SDANN, SDNNi, rMSSD, pNN50 HF, LF, TP, VLF, ULF DFA-1
Gehi et al., 2009 [22] 88% 288 50–57 Men
(0/100)
AHA y NHLBI No HF, LF, TP, VLF, ULF No
Assoumou et al., 2010 [26] 94% 1010 64–66 Both
(60/40)
NCEP-ATP III No TP, HF, LF, VLF, ULF, LF/HF No
Rasic-Milutinovic et al., 2010 [27] 88% 47 50–60 Both
(60/40)
NCEP ATP III SDNN, rMSSD HF, LF, LF/HF, TP, VLF No
Poliwczak et al., 2013 [24] 94% 80 50–55 Men
(0/100)
IDF SDNN, SDANN, SDNNi, rMSSD, pNN50 HF, LF, LF/HF, TP, VLF, ULF No
Jarczok et al., 2013 [28] 88% 2441 18–67 Both
(24/76)
IC SDNN, rMSSD HF, LF, LF/HF No
Wulsin et al., 2016 [23] 94% 1143 40–57 Both
(57/43)
IC SDNN, rMSSD No No
Yoo et al., 2016 [32] 94% 1200 50–60 Both
(60/40)
NCEP ATP III SDNN, SDANN, rMSSD No No
Balcioglu et al., 2016 [29] 94% 150 48–74 Both
(65/35)
NCEP ATP III SDNN, SDANN, SDNNi, rMSSD, pNN50 No No
Ma et al., 2017 [11] 94% 401 46–64 Both
(41/59)
NCEP ATP III SDNN, rMSSD, pNN50, pNN20 HF, LF, LF/HF, TP, VLF SD1, SD2, SD1/SD2, Multiscale entropy
Slušnienė et al., 2019 [30] 81% 106 50–55 Both
(49/51)
NCEP ATP III SDNN, SDANN, SDNNi, rMSSD, pNN50 HF, LF, LF/HF, VLF No
MacIorowska et al., 2020 [25] 69% 118 34–58 Both
(32/86)
IDF SDNN, rMSSD, pNN50 HF, LF, LF/HF, TP No

NCEP-ATP III: National Cholesterol Education Program’s Adult Treatment Panel III. IDF: International Diabetes Federation. AHA: American Heart Association. NHLBI: National Heart Lung and Blood Institute. Alberti et al., 2009 [33]. IC: Consensus definition from several national and international organizations. F/M: ratio female/male expressed in percentage (%).